跳至主要内容
临床试验/JPRN-jRCT2031210255
JPRN-jRCT2031210255已完成3 期

Phase 3 Clinical Study of JTE-061 Cream - Randomized Vehicle-controlled Study (Part 1) and Extension Study (Part 2) in Patients with Atopic Dermatitis

emoto Takanori0 个研究点目标入组 216 人开始时间: 2021年8月18日最近更新:
适应症

试验速览

阶段
3 期
状态
已完成
发起方
入组人数
216

研究概览

简要总结

When JTE-061 cream 1% was administered once daily for 8 weeks to patients with AD, improvements in the IGA, EASI, %BSA affected, pruritus NRS, and Skindex-16 were noted as compared to the vehicle cream. When JTE-061 cream 1% was administered once daily for up to 24 weeks to patients with AD, the plasma concentration was low, and treatment with JTE-061 was generally safe. The efficacy of JTE-061 cream 1% in the treatment of AD was maintained for up to 24 weeks.

研究设计

研究类型
Interventional

入排标准

年龄范围
>= 12age old 至 ot applicable(—)
性别
All

入选标准

  • 1. Japanese patients aged >= 12 years at informed consent who can visit the study site as an outpatient
  • 2. Patients with clinical diagnosis of AD according to the criteria of the Japanese Dermatological Association prior to or at informed consent
  • 3. Patients whose IGA score, EASI score, and %BSA affected meet the criteria specified in the study protocol

排除标准

  • 1. Patients with a history of or current significant dermatologic or inflammatory condition that, in the investigator's opinion, would make it difficult to interpret data or assessments during the study
  • 2. Patients with a history of or current acute active bacterial, fungal, or viral (e.g., herpes simplex, herpes zoster, and varicella))skin infection within 1 week prior to Week 0
  • 3. Patients who have used any prohibited therapy specified in the study protocol within the indicated period before Week 0
  • 4. Patients with serious concomitant disease(s)
  • 5. Patients with a history of or current cancer within 5 years prior to screening visit

研究者

发起方
emoto Takanori

相似试验